The Thrombopoietin Receptor Agonist Eltrombopag Inhibits Human Cytomegalovirus Replication Via Iron Chelation

The thrombopoietin receptor agonist eltrombopag was successfully used against human cytomegalovirus (HCMV)-associated thrombocytopenia refractory to immunomodulatory and antiviral drugs. These effects were ascribed to the effects of eltrombopag on megakaryocytes. Here, we tested whether eltrombopag...

Descripción completa

Detalles Bibliográficos
Autores principales: Vogel, Jens-Uwe, Schmidt, Sophie, Schmidt, Daniel, Rothweiler, Florian, Koch, Benjamin, Baer, Patrick, Rabenau, Holger, Michel, Detlef, Stamminger, Thomas, Michaelis, Martin, Cinatl, Jindrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017049/
https://www.ncbi.nlm.nih.gov/pubmed/31861948
http://dx.doi.org/10.3390/cells9010031

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017049/
https://www.ncbi.nlm.nih.gov/pubmed/31861948
http://dx.doi.org/10.3390/cells9010031

Ejemplares similares